Form of Warrant, to be issued by PLx Pharma Inc. to the Investors on June 14, 2017.
Opinion of Jackson Walker L.L.P.
Amended and Restated Patent License Agreement, dated December 11, 2009
Amendment No. 1 to Amended and Restated Patent License Agreement, dated April 15, 2011
Amendment No. 2 to Amended and Restated Patent License Agreement, dated December 17, 20 11
Consent of Jackson Walker L.L.P. (included in Exhibit 5.1)
Press Release, issued by PLx Pharma Inc. on June 12, 2017
Placement Agency Agreement, dated as of June 9, 2017, by and between PLx Pharma Inc. and Raymond James & Associates, Inc.
Form of Securities Purchase Agreement
* Filed as exhibit to Original Form 8-K filed with the
Securities and Exchange Commission on June 12, 2017
Confidential treatment requested.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
President and Chief Executive Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
General statement of acquisition of beneficial ownership - Nov. 20, 2017
Dipexium Pharmaceuticals, Inc. Just Filed Its Quarterly Report: Loss per share Basic... - Nov. 9, 2017
Departure of Directors or Certain - Oct. 27, 2017